Peter Clark to Disease-Free Survival
This is a "connection" page, showing publications Peter Clark has written about Disease-Free Survival.
Connection Strength
0.913
-
Balci M, Glaser ZA, Chang SS, Herrell SD, Barocas DA, Keegan KA, Moses KA, Resnick MJ, Smith JA, Penson DF, Scarpato K, Clark PE. Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. J Cancer Res Ther. 2021 Apr-Jun; 17(2):420-425.
Score: 0.181
-
Glaser ZA, Love HD, Guo S, Gellert L, Chang SS, Herrell SD, Barocas DA, Penson DF, Cookson MS, Clark PE. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. Urol Oncol. 2017 05; 35(5):286-293.
Score: 0.135
-
Morgan TM, Tang D, Stratton KL, Barocas DA, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol. 2011 Jun; 59(6):923-8.
Score: 0.089
-
Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA, Clark PE. Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? J Urol. 2008 Jun; 179(6):2152-7.
Score: 0.074
-
Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 2007 Aug; 189(2):429-36.
Score: 0.070
-
Phillips JJ, Hall MC, Lee WR, Clark PE. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Oncol. 2007 May-Jun; 25(3):196-200.
Score: 0.069
-
Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005 Feb 01; 103(3):546-52.
Score: 0.059
-
Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004 Oct; 172(4 Pt 1):1342-7.
Score: 0.058
-
Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J, Raghavan D. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urol Oncol. 2019 12; 37(12):900-906.
Score: 0.041
-
Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA, Barocas DA. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology. 2014 Jun; 83(6):1309-15.
Score: 0.028
-
Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA. Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. J Urol. 2010 Mar; 183(3):990-6.
Score: 0.021
-
Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA, Barocas DA. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol. 2009 Nov; 182(5):2291-5.
Score: 0.020
-
Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
Score: 0.019
-
Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Brachytherapy. 2008 Oct-Dec; 7(4):286-9.
Score: 0.019
-
Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006 Feb; 67(2):349-53.
Score: 0.016
-
Gwynn ES, Clark PE, Hall MC. Recent advances in the treatment of bladder cancer. Expert Rev Anticancer Ther. 2005 Dec; 5(6):1023-30.
Score: 0.016